ERBB2 and breast neoplasm: Findings from both cohorts similarly revealed that HER2-low breast tumors had higher frequency of PIK3CA mutations, lower frequency of TP53 mutations, and lower pCR rates with neoadjuvant therapy as compared with HER2-zero breast tumors.